“Our mission is to contribute to the improvement and protection of the health of populations across the world. The fair sharing of the value created with all our employees is the foundation of our business model. The sustainability of MedinCell is an essential condition for achieving our objectives.”
Raison d’être of MedinCell voted by the General Assembly in September 2019
By improving patient’s adherence and compliance to treatments
WHO estimates that one patient in two does not start or does not continue to follow their treatment and that adherence improvement would have a greater impact than any improvement in specific medical treatments.
(World Health Organization: Adherence to Long-Term Therapies, Evidence for Actions – 2003)
By ensuring accessibility of treatment
Our innovative technologies associated with our “Global Access” strategy should allow patients around the world to benefit from the same treatments, regardless of their income or health systems.
By Reducing pharmaceutical residues, a major environmental challenge
Our technologies must help reduce the environmental impact of drugs by reducing the amount of active ingredient needed compared to the same oral treatment and by preventing unused drugs from being thrown out of recycling channels
Collaborate in the interests of patients
Collaboration is at the heart of our business model. It is essential to offer new therapeutic options to patients around the world. We have developed a high value network of partners bringing together players from the pharmaceutical industry and academic research as well as leading foundations
Share the value created
We favor employee share ownership, which allows fair sharing of the value created and a balanced relationship between management and all employees. Aligning the interests of all our stakeholders (employees, shareholders, partners) is an essential element of our business strategy.
We foster diversity and well-being at work
Our multicultural and talented team makes all the difference. We provide a healthy and respectful work environment for all.
This corporate responsibility policy defines the principles and objectives, consistent with our mission and values, that all MedinCell employees must adhere to and contribute to in their professional practices. It provides a framework for integrating economic and environmental imperatives into MedinCell’s activities to achieve long-term sustainability and value creation. Our Policy is based on five strategic pillars:
We put innovation excellence at the service of patients by designing purposeful technologies enabling new products and accessible therapies. To pursue this goal, we:
Our multicultural and talented team makes all the difference. We provide a healthy and respectful work environment for all. We believe that sharing the success and value creation with all employees and internal stakeholders is the key to ensuring our sustainability. We will continue to:
We believe that sharing value with our employees and aligning the interests of all stakeholders is essential to our success and sustainability. We believe that all healthcare stakeholders, from patients to industry partners, must work together to enable the development of sustainable, mutually beneficial healthcare systems. We also believe in information that allows everyone to make an informed decision. We therefore:
With Global Health at the heart of our vision, we strive to minimize our impact on the environment. At our own level we:
We value trust, respect, and integrity in all our interactions and activities. To achieve this pledge, we:
Our global access commitment aims to guarantee the accessibility of our treatments, in particular those that we develop with the support of Foundations and International Health Agencies.
mdc-WWM • In accordance with the Global Access strategy of both partners and to ensure a significant impact on women’s lives, the objective is to make the product widely available. Affordable pricing in emerging economies will help eliminate cost as a barrier to increased availability and voluntary access to the product. High demand among women and girls for long acting contraceptive options illustrate the potential for market growth and measurably improving maternal, newborn and child health. MedinCell could receive up to $ 24 million from the Bill and Melinda Gates Foundation for the development of this project. The Bill and Melinda Gates Foundation also has a non-exclusive license for non-commercial market in low- and middle-income countries.
mdc-STM • The goal is to neutralize anopheles mosquitoes, which carry and transmit the malaria parasite, after they bite treated populations. mdc-STM could break the chain of transmission with a single injection of ivermectin active for 3 months which will make it possible to remove some of the logistical barriers to the adoption of mass treatments, since it will not require the regular renewal of the treatment, typically associated with oral forms whose duration of effectiveness is too short. MedinCell received a $6.4 million grant from international health agency Unitaid, which is committed to accelerating the impact of long-acting technologies in developing countries. low and middle income
Codes of Ethics
Session en français
Rendez-vous le mardi 2 mai à 18h30 pour une vidéoconférence dédiée à l'approbation de UZEDY™
On Tuesday, May 2 at 7.30 pm (CEST) participate in our videoconference dedicated to the approval of UZEDY™